Avenzo Therapeutics News and Activities

Acquisition, funding and merger involving Avenzo Therapeutics.

• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

View the org chart displaying its 33 main executives

Most searched biographies at Avenzo Therapeutics

• Athena Countouriotis, Co-Founder, Chief Executive Officer and Chai...
• Simeon George, Director
• Garry Nicholson, Independent Director

Popular executive movements at Avenzo Therapeutics

• Sherry Wunder, who was Director, Clinical Data Management, is promoted to Senior Director, Clinical Data Management  (posted on March 31 2026).
• Heather Sun, who was Director, Business Development, is promoted to Senior Director, Business Development  (posted on March 31 2026).
• Robyn Gavin, who was Associate Director, Medical Writing, is promoted to Director, Medical Writing  (posted on March 31 2026).

Click here to view some more movements at Avenzo Therapeutics

Create your alert
to follow the executive moves at Avenzo Therapeutics.

Avenzo Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Avenzo Therapeutics

• Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study | Avenzo Therapeutics
• Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting | Avenzo Therapeutics
• Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium | Avenzo Therapeutics
• Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin | Avenzo Therapeut
• Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer | Avenzo Therapeutics
• Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC | Avenzo Therapeutics
• Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium | Avenzo Therapeutics
• Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
• Avenzo Therapeutics Announces $60 Million Series B Financing | Avenzo Therapeutics
• Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
• View more press releases Close

Social media about Avenzo Therapeutics

• Avenzo Therapeutics on Wikipedia, Google News & Yahoo Finance
• Avenzo Therapeutics on LinkedIn, X (Twitter) & YouTube